PhoenixBio Co (TSE:6190) Operating Margin %: 9.53% (As of Mar. 2026)


TSE:6190 PhoenixBio Co Ltd TSE:6190
62 GF Score
Price 円324.00
GF Value 円361.16
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is PhoenixBio Co Operating Margin %?

PhoenixBio Co TSE:6190 -7.16% 62 Operating Margin % is 9.53% as of Mar. 2026. GuruFocus rates TSE:6190 with a GF Score™ of 62/100 and a GF Value™ of 円361.16 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 944 Biotechnology companies, PhoenixBio Co ranks better than 76.17% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. PhoenixBio Co's Operating Income for the six months ended in Mar. 2026 was 円77 Mil. PhoenixBio Co's Revenue for the six months ended in Mar. 2026 was 円809 Mil. Therefore, PhoenixBio Co's Operating Margin % for the quarter that ended in Mar. 2026 was 9.53%.

The historical rank and industry rank for PhoenixBio Co's Operating Margin % or its related term are showing as below:

TSE:6190' s Operating Margin % Range Over the Past 10 Years
Min: -29.77   Med: -10.21   Max: 23.94
Current: 5.29


TSE:6190's Operating Margin % is ranked better than
76.17% of 944 companies
in the Biotechnology industry
Industry Median: -86.83 vs TSE:6190: 5.29

PhoenixBio Co's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

PhoenixBio Co's Operating Income for the six months ended in Mar. 2026 was 円77 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was 円83 Mil.

Warning Sign:

PhoenixBio Co Ltd has recorded a loss in operating income at least once over the past 3 years.


PhoenixBio Co  (TSE:6190) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


PhoenixBio Co Operating Margin % Related Terms


PhoenixBio Co Operating Margin % Historical Data

* Premium members only.

The historical data trend for PhoenixBio Co's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PhoenixBio Co Operating Margin % Chart

PhoenixBio Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.65 23.94 0.65 -9.22 5.29

PhoenixBio Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.94 -12.54 -5.74 0.75 9.53

TSE:6190 vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, PhoenixBio Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhoenixBio Co Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhoenixBio Co's Operating Margin % distribution charts can be found below:

* The bar in red indicates where PhoenixBio Co's Operating Margin % falls into.


TSE:6190
62GF Score
PhoenixBio Co Ltd TSE:6190
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PhoenixBio Co Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

PhoenixBio Co's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (A: Mar. 2026 ) / Revenue (A: Mar. 2026 )
=82.771 / 1565.532
=5.29 %

PhoenixBio Co's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=77.094 / 809.18
=9.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 9.53% mean?
PhoenixBio Co (TSE:6190) has a Operating Margin % of 9.53% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on PhoenixBio Co and its competitors. According to the industry distribution chart, PhoenixBio Co ranks #225 out of 944 companies in the Biotechnology industry, placing it in the top 23.8%.
Is PhoenixBio Co's Operating Margin % too high?
PhoenixBio Co's current Operating Margin % is 9.53%. Based on the distribution chart, PhoenixBio Co ranks #225 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PhoenixBio Co has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PhoenixBio Co's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PhoenixBio Co ranks #225 out of 944 companies for Operating Margin %. This places PhoenixBio Co in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on PhoenixBio Co and its competitors. PhoenixBio Co's current Operating Margin % is 9.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhoenixBio Co stock overvalued right now?
Based on GuruFocus' analysis, PhoenixBio Co (TSE:6190) is currently considered Modestly Undervalued. The stock's GF Value™ is 円361.16, compared to a current price of 円324.00 — trading 10.3% below its estimated fair value. The current Operating Margin % is 9.53%. PhoenixBio Co's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For PhoenixBio Co (TSE:6190), the current Operating Margin % is 9.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PhoenixBio Co (TSE:6190) Overvalued in 2026?

Based on GuruFocus' analysis, PhoenixBio Co stock appears to be undervalued. The current stock price of 円324.00 is trading 10.3% below its estimated GF Value™ of 円361.16. GuruFocus considers PhoenixBio Co to be Modestly Undervalued.

Key valuation signals for TSE:6190:

  • Operating Margin %: 9.53%
  • GF Value™: 円361.16 vs. price of 円324.00 (10.3% below fair value)
  • GF Score™: 62/100 with 5 warning signs

No single metric tells the full story. See the TSE:6190 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PhoenixBio Co Business Description

Address 3-4-1, Kagamiyama, Hiroshima Prefecture, Higashi-Hiroshima, JPN, 739-0046
PhoenixBio Co Ltd conducts study services for drug discovery and early development. It provides outsourcing services for drug development. The Company uses PXB-Mouse to conduct the study. Its services include pharmacokinetics-related tests, safety tests, and hepatitis virus (HBV / HCV) related drug efficacy tests. Geographically, the company generates the majority of its revenue from USA.
62GF Score

Get the complete analysis for TSE:6190

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円324.00
Price
円361.16
GF Value